Najnowsze informacje o produktach
GEA introduces pharma separator lines aseptic and pure for biopharmaceutical separation processes
22 Aug 2022
With a view to the very different hygiene requirements in individual pharmaceutical processes, GEA engineers developed a new, fully comprehensive portfolio of plug & produce pharmaceutical separators. GEA presents the separator lines aseptic and pure at ACHEMA 2022 in Frankfurt. The aseptic and pure separator lines are used in all pharmaceutical and biotechnological downstream processes and meet customer-specific as well as process-required demands. GEA sees the uncompromising hygienic design reliability and the possibility of maximum yield in the respective processes as the decisive plus points of aseptic and pure.
The pharmaceutical separator lines "aseptic" and "pure" are developed to the highest GEA standards at the German GEA Westfalia Separator plant in Oelde, where they are built and tested. All features for pharmaceutical cleanliness requirements such as an automatic CIP (Cleaning-in-Place), SIP (-Sterilization-in-Place), easy validation and a high-end qualification package are included. In addition, the pharmaceutical separators support GEA customers in their quality standard reviews with the help of the cGMP validation process ("Current Good Manufacturing Practice, cGMP).
GEA separator line aseptic
The aseptic line includes SIP processing and stands for the highest hygienic pharmaceutical requirements. It offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products.
GEA's separator line aseptic including SIP offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)
GEA separator line pure
The pure line gives highest variability and is perfectly tailored to the diverse process requirements of the biopharma industry. It is recommended for customers with applications with varying hygienic requirements, such as for food supplements, therapeutic proteins, pharmaceutical extractions, and in the recovery of extracellular and intracellular enzymes. Here, the separator line pure offers the highest variability in the selection of required hygienic components.
GEA presents the separator pure line at ACHEMA 2022. (Photo: GEA)
flexChange 3-in-1 bowl concept from GEA for producers with frequent product changes
The GEA flexChange 3-in-1 bowl concept of the new separator series aseptic and pure ensures high flexibility, which means a plus in competitiveness especially for Contract Manufacturing Organizations (CMO) and operators of pilot plants. The principle: the customer selects the bowl variant ideally suited to his products with solid content from 5 vol% to 35 vol% or higher, depending on product. This results in maximum yield with every product change. One GEA Pharma Skid with flexChange concept thus replaces three plants.
Contact
Dr. Michael Golek
Media Relations
GEA Group Aktiengesellschaft
Peter-Müller-Str. 12
40468
Düsseldorf
Germany
+49 211 9136-0
O GEA
GEA jest jednym z największych dostawców dla przemysłu przetwarzania żywności i wielu innych sektorów, w 2019 roku spółka wygenerowała skonsolidowane przychody na poziomie 4,9 miliarda euro.
